1.Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.
Myong Cheol LIM ; Leslie M RANDALL
Journal of Gynecologic Oncology 2017;28(4):e51-
No abstract available.
Ovarian Neoplasms*
2.An immunohistochemical evaluation of c-erbB-2 expression in epithelial ovarian cancer.
Kyung Tai KIM ; Sam Hyun CHO ; Youn Yeoung HWANG ; Hyung MOON ; Jai Auk LEE ; Young Hye KO ; Jung Dal LEE
Korean Journal of Obstetrics and Gynecology 1993;36(8):3334-3342
No abstract available.
Ovarian Neoplasms*
3.Three ongoing intraperitoneal chemotherapy trials in ovarian cancer.
Journal of Gynecologic Oncology 2012;23(2):75-77
No abstract available.
Ovarian Neoplasms
4.Recent advances in ovarian cancer treatment.
Journal of the Korean Medical Association 2016;59(3):164-166
No abstract available.
Ovarian Neoplasms*
5.Clinical significance of postoperative CA-125 level after primary cytoreductive surgery in ovarian cancer.
Journal of Gynecologic Oncology 2008;19(4):279-279
No abstract available.
Ovarian Neoplasms
6.Clinical significance of postoperative CA-125 level after primary cytoreductive surgery in ovarian cancer.
Journal of Gynecologic Oncology 2008;19(4):279-279
No abstract available.
Ovarian Neoplasms
7.Management of Advanced Epithelial Ovarian Cancer.
Korean Journal of Obstetrics and Gynecology 1999;42(8):1647-1654
No abstract available.
Ovarian Neoplasms*
8.A Short-Term In-Vitro Chemosensitivity Test for Ovarian Cancer: Nuclear Damage Assay.
Young Tak KIM ; Kwan Ja JI ; Yong Man KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1997;8(1):47-54
No abstract available.
Ovarian Neoplasms*
9.Do we need a better marker for successful ovarian cancer surgery?.
Journal of Gynecologic Oncology 2017;28(1):e21-
No abstract available.
Ovarian Neoplasms*
10.Outcomes of patients undergoing fertility-sparing surgery for ovarian cancers: 5- year review in a tertiary hospital
Dy-Echo Ana Victoria V. ; Luna Jericho Thaddeus P.
Philippine Journal of Reproductive Endocrinology and Infertility 2010;7():14-21
A five-year retrospective study was conducted to determine the fertility and clinical outcomes of ovarian cancer patients undergoing fertility-sparing surgery (FSS). Medical records were evaluated. Menstrual, fertility and clinical outcomes were measured. Of the 44 cases evaluated, 41 (93.18%) were stage I, while 3 (6.82%) had advanced stages. Complete surgical staging was done in 19 (43.18%) patients. All had restoration of menses 1-2 months after surgery with no significant amenorrhea among those given platinum-based chemotherapy. There were 15 successful pregnancies (83.33%). There were only 5 patients (27.78%) with infertility, and 8 (18.18%) cases of tumor persistence/recurrence, all of malignant germ cell tumors without adjuvant chemotherapy. This study confirms FSS as a safe and acceptable treatment for reproductive-age women < 30 years old with no history of infertility, with either stage I epithelial tumors (low malignant potential and frank carcinoma) or malignant germ cell tumors with assured adjuvant chemotherapy.
OVARIAN NEOPLASMS
Result Analysis
Print
Save
E-mail